Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Nephrol. Dec 25, 2025; 14(4): 109767
Published online Dec 25, 2025. doi: 10.5527/wjn.v14.i4.109767
Published online Dec 25, 2025. doi: 10.5527/wjn.v14.i4.109767
Hepatitis B and chronic kidney disease: Bench to bedside
Surender Singh, Rajani Singh, Amit Goel, Department of Hepatology, Sanjay Gandhi Post
Anupma Kaul, Department of Nephrology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow 226014, Uttar Pradesh, India
Author contributions: Singh S contributed to review of literature, manuscript writing and editing; Singh R contributed to manuscript writing; Kaul A contributed to manuscript editing; Goel A contributed to conceptualization, review of literature, manuscript writing and editing.
Conflict-of-interest statement: All authors declare that they have no conflict of interest to disclose.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Amit Goel, Professor, Department of Hepatology, Sanjay Gandhi Post
Received: May 21, 2025
Revised: August 17, 2025
Accepted: November 27, 2025
Published online: December 25, 2025
Processing time: 216 Days and 14.5 Hours
Revised: August 17, 2025
Accepted: November 27, 2025
Published online: December 25, 2025
Processing time: 216 Days and 14.5 Hours
Core Tip
Core Tip: Hepatitis B virus (HBV) infection is prevalent in chronic kidney disease (CKD) patients, particularly those on hemodialysis. Vaccination against hepatitis B is recommended for all those with CKD. Highly effective oral antiviral drugs with a strong barrier to resistance are available for HBV treatment but they require dose adjustment based on a patients' creatinine clearance. Given the ever-increasing number of patients with CKD and HBV, it is crucial to raise awareness regarding its modes of transmission, prevention strategies, and available treatment modalities.